Torrent Pharmaceuticals Ltd.

NSE: TORNTPHARM | BSE: 500420 | ISIN: INE685A01028 | Industry: Pharmaceuticals
| Expensive Performer
3579.1000 -20.20 (-0.56%)
NSE Sep 05, 2025 15:31 PM
Volume: 94,944
 

3579.10
-0.56%
HDFC Securities
Downside risks: delay in resolution of Dahej (OAI) and Indrad (WL), slower growth in India and launch delays in the US. We resume coverage on Torrent Pharma (TRP) with a Buy. Torrent has re-rated substantially in the past three years on the back of strong execution particularly in branded markets. Despite rich valuation, we recommend Buy as TRP offers a solid India franchise, robust earnings growth and superior return profile which justifies the premium over peers. TRP would generate Rs56bn of FCF over FY19-22E. Our TP of Rs 2,250 is based on 15x FY22 EV/EBIDTA implying a target PE of 28x.
Torrent Pharmaceuticals Ltd. is trading above its 200 day SMA of 3300.6
More from Torrent Pharmaceuticals Ltd.
Recommended